VIRBAC CORPORATION NAMES ROBERT "MAC" MACGREGOR VICE PRESIDENT, INDUSTRIAL OPERATIONS

Fort Worth, Texas (May 18, 2015) – Virbac Corporation today announced that Mr. Robert "Mac" MacGregor has been named Vice President, Industrial Operations, effective immediately. In this role, Mr. MacGregor will be responsible for North American Industrial Operations, encompassing planning, directing and coordinating all manufacturing activities, to efficiently supply customers based upon their needs and pharmaceutical/regulatory requirements.

Mac will be the designated Site Manager for Virbac's Bridgeton, Missouri facility and will report to Paul Hays, President & CEO North America and functionally to Marc Bistuer, Head Global Industrial & Quality Assurance. Paul Hays said, "Mac brings over 30 years of rich experiences in manufacturing; with nearly 25 years in FDA pharmaceutical operations. We are delighted for him to join Virbac as we pursue our expansion plans and implement our Quality System Improvement Plan."

Most recently, Mac was with TEVA where he held the positions of General Manager for an antibiotic plant, VP Operations for TEVA Animal Health, Director of Engineering for the entire API Division and General Manager for an API plant. Prior to TEVA, Mac was Plant Manager for an analgesics plant in St. Louis belonging to Rhodia (Solvay Group). He started his career with Unilever in the UK followed by management roles at DuPont, both in the UK and US.

Mr. MacGregor received both his BS in Chemistry and his 3 years of post-graduate studies in Quantum Mechanics from the University of Bristol.

One of the world's largest laboratories dedicated exclusively to animal health, Virbac develops, manufactures, and distributes a wide range of products and services intended for the prevention and treatment of common pathologies in companion animals. Virbac Corporation, located in Fort Worth, Texas, is a leading companion animal health company offering products in the heartworm, tick and flea, dermatology, antibiotic, endocrinology, senior care, behavior, critical care nutrition, and oral hygiene markets.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…